The FDA is wrong to pull life-saving COVID-19 antibody treatments

Published January 26, 2022 8:33pm ET



The Food and Drug Administration suddenly decided to withdraw its emergency use authorization of two COVID-19 antibody treatments this week, leaving hundreds of patients who depend on them in the lurch.

The monoclonal antibody treatments made by Regeneron Pharmaceuticals and Eli Lilly have proven invaluable in fighting off hospitalization and death from the virus, especially against the delta variant. I would know: My grandmother was one of the patients in Florida who benefited from this treatment. Fully vaccinated and boosted, she tested positive for COVID-19 last month and was able to receive an antibody infusion within a few days. It improved her condition dramatically, and she has since recovered. But she might not have if she did not have access to this treatment.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.